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Abstract 
Background: Thalidomide and its analogs, lenalidomide and pomalidomide (referred to as immunomodulatory 
imide drugs or IMiDs) have been known to treat multiple myeloma and other hematologic malignancies as well as to 
cause teratogenicity. Recently the protein cereblon was identified as the primary target of IMiDs, and crystallographic 
studies of the cereblon–IMiDs complex showed strong enantioselective binding for the (S)‑enantiomer of IMiDs.
Results: Using the structures of cereblon and IMiDs [both (S)‑enantiomers and (R)‑enantiomers] we performed 
docking simulations in order to replicate this enantiomeric selectivity and to identify the region(s) contributing to 
this selectivity. We confirmed the enantioselective binding of IMiDs to cereblon with high accuracy, and propose that 
the hairpin connecting the β10–β11 region of cereblon (residues 351–355) contributes to this selectivity and to the 
increased affinity with IMiDs.
Conclusions: Our docking results provide novel insights into the binding mode of IMiD‑like molecules and contrib‑
ute to a deeper understanding of cereblon‑related biology.
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Background
In the 1950s, thalidomide [α-(N-phthalimido)glutarim-
ide] was introduced and taken by many pregnant women 
as a sedative/anti-nausea drug (Bartlett et  al. 2004; Ito 
et  al. 2011; Shortt et  al. 2013). In the early 1960s, how-
ever, the drug was banned from the market because of its 
teratogenic potential (Mcbride 1961; Lenz et  al. 1962). 
Despite this notorious effect, intensive research has 
been carried out with thalidomide due to its efficacy of 
inhibiting tumor necrosis factor (TNF)-α secretion and 
treating multiple myeloma and other hematologic malig-
nancies (Sheskin 1965; Singhal et  al. 1999). In this con-
text, attempts to augment the effect of the drug resulted 
in the development of its analogs, lenalidomide and 
pomalidomide. This class of compounds is referred to 
as immunomodulatory imide drugs or IMiDs, and these 
compounds share two structural elements, the glutarim-
ide moiety and the phthaloyl moiety (Fig. 1a). Although 
apremilast was approved as an analog of IMiDs in 2014 
by FDA, apremilast was not included in the current 
study. Because while both apremilast and thalidomide 
share a phthaloyl moiety structure, apremilast lacks the 
glutarimide moiety and thus fails to bind to cereblon, the 
target of thalidomide action.
Due to chirality, the drugs have two isomeric forms 
and it is difficult to isolate one enantiomer from the 
other, because both enantiomers rapidly interchange 
in  vivo (Eriksson et  al. 1995; Lepper et  al. 2006). Since 
the discovery of the teratogenic potential of IMiDs, 
a number of studies have proposed many hypotheses 
about their mechanisms, including oxidative stress (Par-
man et  al. 1999) and anti-angiogenesis (Therapontos 
et al. 2009). These efforts, however, have not completely 
elucidated the mechanism of IMiDs-induced terato-
genicity and other therapeutic mechanisms (Bartlett 
et  al. 2004; Ito et  al. 2011). In 2010, the discovery that 
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the protein cereblon was the primary target of IMiDs 
opened a new avenue in IMiD research (Ito et al.). Cer-
eblon protein has three domains; the amino terminal 
domain (NTD), the α-helical bundle domain (HBD), and 
the carboxy-terminal domain (CBD), and its sequence 
is highly conserved between different species (Ito et  al. 
2011; Shortt et al. 2013). This protein is a part of dam-
age-specific DNA binding protein 1 (DDB1)/cullin4 E3 
ubiquitin ligase complex and acts as the recruitment site 
for the ubiquitylation of substrate proteins, thus promot-
ing their degradation (Ito et al. 2011; Shortt et al. 2013). 
Recently, the crystal structures of cereblon bound to 
IMiDs were solved and these structures revealed that 
the (S)-enantiomers of IMiDs bind to the protein, and 
the myeloid ecotropoic viral insertion site homeobox  2 
(MEIS2) protein was identified as a substrate of cereblon 
(Fischer et  al. 2014; Chamberlain et  al. 2014) (Fig.  1b). 
A detailed structural analysis revealed that the gluta-
rimide moiety of these compounds recognizes three 
tryptophans (W380, W386, and W400) of the aromatic 
cage (tri-Trp pocket), which are a part of the Tbk1/Ikki 
binding domain (TBD), and the phthalimide moiety is 
exposed to the solvent (Fischer et al. 2014; Chamberlain 
et al. 2014) (Fig. 1c).
Similar to cereblon protein, a number of proteins 
contain such aromatic cages, suggesting that this pro-
tein is bound by other ligands (particularly endog-
enous ligands) (Chamberlain et  al. 2014; Hartmann 
et  al. 2014; Lupas et  al. 2015). More recently, uridine, 
one of the pyrimidine nucleosides, was identified as 
the cellular ligand of cereblon, and was shown to cause 
teratogenicity similar to IMiDs (Hartmann et al. 2014). 
However, other pyrimidine nucleosides such as cyti-
dine or thymidine are shown to have no effect on ter-
atogenicity in  vivo (Hartmann et  al. 2014). Uridine is 
structurally similar to the glutarimide moiety of IMiDs, 
implying that glutarimide- or uridine- like moieties 
induce teratogenicity. Considering the similarity of the 
ligand binding sites between cereblon and other pro-
teins containing aromatic cages, other cationic ligands 
such as methylated lysine and/or arginine residues and 
the ligands containing quaternary ammonium groups 
could competitively bind to the IMiDs binding pocket 
of cereblon.
In this study, using the crystal structures of cer-
eblon, we carried out in silico docking simulations in 
order to replicate these experimental results previously 
reported; the enantiomeric selectivity of IMiDs, and the 
Fig. 1 Structures of IMiDs and cereblon. a Structures of thalidomide, lenalidomide, and pomalidomide. b Schematic representation of enantio‑
meric selectivity for IMiDs. The NTD, HBD, and CBD domains of cereblon are shown in green, blue, and magenta, respectively. c Binding mode of 
IMiDs to cereblon. The CBD domain of the protein is shown in magenta, and the three tryptophans of the aromatic cage (W380, W386, and W400) 
and (S)‑enantiomer of thalidomide [(S)‑thalidomide] are shown in orange and green, respectively (PDB ID: 4CI1). Thalidomide, lenalidomide, and 
pomalidomide are described in ‘thal’, ‘len’, ‘pom’ for short, respectively
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identification of the region of cereblon contributing to 
this selectivity. In addition, we aim to replicate the exper-
imental results obtained with pyrimidine nucleosides 
suggesting the preference of uridine over cytidine or thy-
midine when binding to the cereblon.
Methods
In silico docking simulations
The entire docking protocol was performed using MOE 
2013.08 software package (Molecular Operating Environ-
ment; Chemical Computing Group, Montreal, Quebec, 
Canada) (MOE 2015). 2D molecular structures of IMiDs, 
including (S)-enantiomers [(S)-thalidomide, (S)-lena-
lidomide and (S)-pomalidomide] and (R)-enantiomers 
[(R)-thalidomide, (R)-lenalidomide, (R)-pomalidomide], 
pyrimidine nucleosides (uridine, cytidine, thymidine) 
were obtained from the Nikkaji web service (Nikkaji 
2015), and the 3D structures were modeled using the 
conformational search program in MOE.
The eleven crystal structures of cereblon were obtained 
from the Protein Data Bank (PDB) (Table 1). The Proto-
nate3D program (Labute 2009) was used to assign ioni-
zation states, and to position hydrogen atoms into the 
receptor molecules. Then, after adding partial charges 
under the MMFF94x forcefield and fixing the back-
bone atoms, energy minimization of the receptors was 
performed. Next, the docking site of each receptor was 
assigned using Grid Site Finder Program (MOE 2015), 
which enables the selection of specific residues manually 
and the creation of dummy atoms docked with ligands. In 
this study, using this program we selected three trypto-
phan residues of the aromatic cage (W380, W386, W400) 
of the receptors.
Finally, the ligands were docked with each receptor 
using ASEDock program (Goto et al. 2008). During this 
procedure, flexibility of the ligand atoms was allowed 
and the backbone atoms of the receptors were tethered. 
Following the docking scores (U_dock), the top 10 poses 
of each docking pose were retained and the top scores 
were evaluated in terms of docking scores and poses.
Results
Docking results for IMiDs
The eleven crystal structures of cereblon were obtained 
from the PDB (Table  1), and these structures were 
docked with the (S)-enantiomers [(S)-thalidomide, 
(S)-lenalidomide, and (S)-pomalidomide] and the (R)-
enantiomers [(R)-thalidomide, (R)-lenalidomide, (R)-
pomalidomide] of IMiDs. Using eight out of the eleven 
structures (PDB ID: 4CI1, 4V2Y, 4CI2, 4TZ4, 4V30, 4CI3, 
4V2Z, 4V31), we correctly replicated the enantiomeric 
selectivity, where the docking scores of (S)-enantiomers 
were lower than those of the respective (R)-enantiomers 
(Fig. 2a; Additional file 1: Table S1) and the docking poses 
of (S)-enantiomers were within 2 Å of RMSD value com-
pared to the crystal structures (Additional file  1: Figure 
S1). However, we could not replicate the selectivity when 
using the other three structures (PDB ID: 4TZC, 4TZU, 
3WX2) (Fig.  2b; Additional file  1: Table S1). In these 
cases, some docking results were in contrast to the ear-
lier results (PDB ID: 4TZC and 3WX2), and the overall 
docking scores of (S)-enantiomers were higher compared 
to the correctly replicated structures. We classified these 
‘appropriate’ 8 structures and ‘inappropriate’ 3 structures 
into type A and type B, respectively. A detailed struc-
tural analysis revealed that compared to type A, cereblon 
structures of type B have some differences at the hair-
pin connecting β10–β11 region (residue 351–355). This 
hairpin region in type A is next to the IMiDs binding 
site, whereas this region is disordered or absent in type 
B structures (Fig.  2c). This is in part due to the polym-
erization of cereblon in crystal structures, which distorts 
this hairpin. This phenomenon is unlikely to occur in a 
natural state because no evidence of cereblon monomer 
polymerization has been obtained so far (Chamberlain 
et al. 2014). Therefore, because of this unnatural hairpin 
region, the docking results of type B structures might 
be ‘inappropriate’. Except for type B structures, we con-
firmed the enantiomeric selectivity of IMiDs with high 
accuracy. These results might be due to the increased 
interactions of these molecules with cereblon by their 
amino-phthaloyl-substituted characteristics in type A 
structures.
Docking results for pyrimidine nucleosides
Next, using type A structures we also tried to replicate 
the selectivity of pyrimidine nucleosides i.e. the prefer-
ence of uridine over cytidine and thymidine. We cor-
rectly replicated this selectivity and found that the 
docking scores of uridine were lower than those of the 
Table 1 List of cereblon structures used in this study
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other two pyrimidine nucleosides (Additional file 1: Fig-
ure S2). As previous reports stated (Hartmann et  al. 
2014), these results are attributed to the structural simi-
larity between the uracil moiety of uridine and the glutar-
imide moiety of IMiDs, and the structural discrimination 
of the pyrimidine moiety of cytidine and thymidine. The 
cytosine moiety of cytidine has a different functional 
group compared to the uracil moiety of uridine, resulting 
in inappropriate chemistry for the ligands to bind and in 
higher docking scores for cytidine. As for thymidine, the 
thymine moiety of the ligand has an additional methyl 
group compared to the uracil moiety of uridine, resulting 
in a steric clash with the tryptophan residues and higher 
docking scores for thymidine (Additional file  1: Figure 
S2c). Moreover, type B structures were also tested (Addi-
tional file  1: Figure S3). Because the hairpin connecting 
β10–β11 was incomplete or was oriented in an outer 
space which is further away from the TBD domain of 
cereblon compared with type B structures, an additional 
space was formed. When two of the type B structures 
(PDB ID: 4TZC and 4TZU) were used as receptor for 
docking, pyrimidine nucleosides were docked out of tha-
lidomide binding pocket. While when type A structure 
(e.g. PDB ID: 4CI2) was used, nucleosides were docked 
into the thalidomide binding site (Additional file 1: Figure 
S3). One more point to mention is that according to the 
Fig. 2 Docking results for IMiDs. Eleven cereblon structures were classified into type A (PDB ID: 4CI1, 4V2Y, 4CI2, 4TZ4, 4V30, 4CI3, 4V2Z, and 4V31) 
and type B (PDB ID: 4TZC, 4TZU, and 3WX2). The average docking scores for IMiDs using type A (a) and type B (b) are shown. c Structural differences 
between type A (PDB ID: 4CI1) and type B (PDB ID: 3WX2) cereblon. β10–β11 hairpin of type A and type B cereblon structures are shown in magenta 
and green, respectively. The three tryptophan residues of the aromatic cage (W380, W386, and W400) of cereblon and (S)‑enantiomer of thalidomide 
[(S)‑thalidomide] are shown in orange and magenta, respectively. Thalidomide, lenalidomide, and pomalidomide are described in ‘thal’, ‘len’, ‘pom’ for 
short, respectively
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overlap of the structures (Additional file  1: Figure S3e), 
in the case of 4TZC, if a β10–β11 hairpin exists, the pre-
dicted poses should conflict with it. On the other hand, 
3WX2 extended its hairpin aside compared to 4CI2, and 
this may due to the lack of NTD (Additional file 1: Figure 
S3d, e). In this case, uridine and thymidine were docked 
into the thalidomide binding pocket, and however cyti-
dine was predicted in a reversed form (Additional file 1: 
Figure S3c). Since there was no evidence that pyrimi-
dine nucleosides bind to a space other than thalidomide 
binding site, it is hard to tell the docking poses were cor-
rect and there is less meaningful to compare the dock-
ing scores of these results (Additional file  1: Table S2), 
but only compared the result of uridine/3WX2 with 
thymidine/3WX2, two poses into thalidomide binding 
pocket, uridine is prone to bind to cereblon, due to the 
score showing −40.6 versus −34.4.
Discussion
The β10–β11 hairpin region contributes to the 
enantiomeric selectivity for (S)‑enantiomers
 As mentioned above, the hairpin connecting β10–β11 
could be a key region in the enantiomeric selectivity of 
IMiDs. To better understand the role of this hairpin 
region, we superimposed a type B cereblon structure 
(PDB ID: 4TZC) binding docking poses of (S)-thalid-
omide and (R)-thalidomide, with a type A cereblon 
structure (PDB ID: 4CI1) (Fig.  3a, b). These structures 
revealed that the (R)-thalidomide partially clashed with 
the hairpin region of 4CI1. Thus, for 4TZC the ‘inap-
propriate’ docking results might arise from the widely 
expanded binding pocket due to the disordered hairpin 
structure. These findings also suggest that in case of type 
A structures, the binding of (R)-enantiomers is unfa-
vorable due to the steric hindrance caused by this hair-
pin, next to the IMiDs binding site. Finally, this hairpin 
could contribute to the IMiDs binding affinities, because 
the docking scores of (S)-enantiomers are higher for type 
B structures than for type A (Fig.  2; Additional file  1: 
Table S1). To obtain a deeper insight, we superimposed 
a type A cereblon structure binding the docking pose of 
(S)-thalidomide with a type B cereblon structure (PDB 
ID: 4TZC) binding that of (S)-thalidomide. These struc-
tures revealed that in absence of the β10–β11 hairpin, the 
interaction between the (S)-enantiomer and the β10–β11 
hairpin constructive residues disappear (Fig.  3c). Thus, 
the disorder or absence of β10–β11 hairpin could result 
in decreasing the IMiDs binding affinity. Taken together, 
in addition to previously reported the aromatic cage of 
three tryptophan residues (W380, W386, and W400), the 
hairpin connecting β10–β11 may play an additional role 
in the recognition of IMiDs.
The possible effects of the β10–β11 hairpin in substrate 
recognitions of cereblon
Cereblon, a component of DDB1/cullin4 E3 ubiquitin 
ligase complex, mediates the recruitment and degra-
dation of its target proteins (Ito et al. 2011; Shortt et al. 
2013). Recent experimental results imply that IMiDs act 
as both agonists and antagonists of cereblon (Ito et  al. 
2010; Krönke et  al. 2014; Lu et  al. 2014; Gandhi et  al. 
2014; Krönke et  al. 2015). As an antagonist, the MEIS2 
protein, which acts at various aspects of human growth 
(Capdevila et  al. 1999), was identified as the substrate 
of cereblon that competitively binds to the same bind-
ing site as IMiDs (Fischer et al. 2014). As such, cereblon 
with bound IMiDs prevents the recruitment, ubiquityla-
tion and degradation of MEIS2, resulting in teratogenic-
ity (Fischer et  al. 2014). As an agonist, IMiDs bound to 
cereblon complex promote the binding of some pro-
teins including transcription factors implicated in mul-
tiple myeloma (such as Ikaros and Aiolos) (Krönke et al. 
2014; Lu et al. 2014; Gandhi et al. 2014) or myelodysplas-
tic syndrome (such as casein kinase 1α) (Krönke et  al. 
2015), which otherwise could not bind to cereblon. As a 
result, these events cause the degradation of these tar-
get proteins, resulting in multiple mechanisms of IMiDs 
action. Sequence alignment studies regarding these pro-
teins binding to cereblon with or without IMiDs revealed 
that these proteins do not share high sequence homol-
ogy, suggesting that the ways in which cereblon or the 
cereblon–IMiDs complex recognizes the substrates may 
have some differences. As mentioned above, the β10–
β11 hairpin of cereblon has some difference between 
type A and type B structures due to the polymerization 
of cereblon in crystal structures, thus this hairpin region 
might play an important role with respect to recognition 
of substrate binding. A recent experimental study, which 
implies that this hairpin region only folds upon ligand 
binding, also supports this hypothesis (Lopez-Girona 
et al. 2012). We carried out a 25 ns MD computation of 
human cereblon structure to analyze the movement of 
this hairpin (Additional file  1: Figure S4). This hairpin 
did not move violently throughout our simulation dura-
tion as expected. It is suggested that although β10–β11 
hairpin is useful in substrate recognitions, but high flex-
ibility is not needed. Or the simulation duration was not 
long enough to observe the conformation change of this 
hairpin. Another point should be mentioned here is that 
all crystal structures other than the type A structures 
were derived from only the TBD domain of cereblon, and 
these structures do not cover the overall structures. More 
studies are required to understand the details, such as 
structural identification of the cereblon–MEIS2 complex, 
cereblon–IMiD-substrate complex, and so on.
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Conclusions
In this study, using in silico docking simulations, we 
aimed to confirm the enantioselective binding of IMiDs 
to cereblon and to identify the region of cereblon that 
contributes to this selectivity. For eight out of eleven 
crystal structures of cereblon (referred to as type A), we 
replicated the enantiomeric selectivity of IMiDs with 
the correct docking poses and scores. The results of the 
lower docking scores for lenalidomide and pomalidomide 
compared to those for thalidomide correlate well with the 
previous experimental studies (Fischer et al. 2014; Hart-
mann et  al. 2015). Next, using the pyrimidine nucleo-
sides, we performed docking simulations to replicate the 
previous experimental results that uridine alone binds to 
cereblon (Chamberlain et al. 2014; Hartmann et al. 2014). 
We replicated the preference of uridine to the other puta-
tive ligands with the correct docking scores.
Recent studies about the mechanism of action for cere-
blon have opened a new paradigm about IMiDs biology. So 
far, IMiDs have been considered to bind multiple targets, 
which lead to a variety of mechanisms, such as teratogenic-
ity and the treatment of multiple myeloma (Ito et al. 2011; 
Shortt et al. 2013). In contrast, IMiDs have been recently 
suggested to bind to only one target, cereblon, which 
results in a variety of mechanisms (Handa et al. 2014). This 
concept of cereblon-centered mechanisms is supported 
by the recent findings about the cereblon-induced mecha-
nism of action for IMiDs (Krönke et al. 2014; Lu et al. 2014; 
Fig. 3 β10–β11 hairpin of cereblon could contribute to enantiomeric selectivity and the increased affinity with IMiDs. a Docking poses of (S)‑
thalidomide (green) and (R)‑thalidomide (cyan) using the type B structure (white). b Superimposition of the complex shown in a with the type A 
structure (magenta). c Docking poses of (S)‑thalidomide (magenta) using the type A structure and (S)‑thalidomide (green) using the type B structure. 
β10–β11 hairpin and the three tryptophan residues of the aromatic cage (W380, W386, and W400) of type A cereblon are shown in magenta and 
orange, respectively. Thalidomide, lenalidomide, and pomalidomide are described in ‘thal’, ‘len’, ‘pom’ for short, respectively
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Gandhi et  al. 2014; Krönke et  al. 2015). Therefore, our 
docking results will provide novel insights into the binding 
mode of IMiD-like molecules and contribute to a deeper 
understanding of cereblon-related biology.
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